Cargando…
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer
BACKGROUND: At diagnosis, more than 80% of patients with pancreatic cancer (PC) suffer from significant weight loss due to malnutrition which is a major concern for patient management, and this may negatively impact treatment outcomes and patient prognosis. PATIENTS AND METHODS: We performed an obse...
Autores principales: | Giordano, Guido, Cincione, Raffaele Ivan, Losavio, Francesca, Senia, Tiziano, Aquilini Mummolo, Arianna, Pacilli, Mario, Lizzi, Vincenzo, Bruno, Giuseppina, Piscazzi, Annamaria, Conteduca, Vincenza, Landriscina, Matteo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485404/ https://www.ncbi.nlm.nih.gov/pubmed/37155993 http://dx.doi.org/10.1093/oncolo/oyad101 |
Ejemplares similares
-
nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017) -
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
por: Al-Hajeili, Marwan, et al.
Publicado: (2014) -
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
por: Alvarez, R, et al.
Publicado: (2013) -
Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
por: De Luca, Rossella, et al.
Publicado: (2018) -
Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'
por: Alvarez, R, et al.
Publicado: (2014)